HOME >> MEDICINE >> NEWS
Test to predict cardiovascular risk in heart attack patients not yet appropriately used

BNP levels were greater among sub-groups of patients who were less likely to have BNP levels measured at all," Roe continued. "It appears that physicians were ordering tests for those patients who would already be considered at the highest risk of early mortality, such as those with congestive heart failure on hospital presentation. More randomized trials are needed to specifically identify those patients who should be tested and those who would benefit the most from this new test."

To understand more clearly how the BNP test is used in the U.S., Roe and his colleagues consulted the national quality improvement initiative known as CRUSADE, which stands for "Can Rapid risk stratification of UnStable Angina patients suppress aDverse outcomes with Early implementation of the ACC/American Heart Association (AHA) guidelines."

CRUSADE continuously gathers data from participating hospitals that treat patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) including patients with a certain type of heart attack known as non-ST-segment elevation myocardial infarction. These patients come to hospital emergency rooms with heart attack symptoms and are found to have chemical signs of heart muscle death and/or electrocardiogram tests showing areas of ischemia in the heart. About 1.3 million Americans are hospitalized each year with NSTE ACS.

During a 20-month period ending in 2004, 30,324 NSTE ACS patients were treated at 312 CRUSADE hospitals. A total of 19.4 percent of those patients had their BNP levels measured.

'The finding that one in five patients received the test is in line for something as new as this type of laboratory test," Roe. "However, at this point it is not being used in the right patients. It appears that the test is predominantly being ordered in older patients with a history of heart failure or signs of heart failure on presentation. These patients are already at a high risk of early mortality based upon
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
14-Mar-2006


Page: 1 2 3

Related medicine news :

1. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
2. Novel candidate biomarker for heart failure also strongly predicts risk of death
3. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
4. Childrens brain responses predict impact of sleep loss on attention
5. Simple test predicts 6-year risk of dementia
6. USC researchers show that molecular markers predict tumor recurrence
7. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
8. Exercise test may help predict mortality risk in heart failure patients
9. Researchers use MRI to predict recovery after spinal cord injury
10. High pretreatment PSA velocity predicts worse outcome
11. Why predicting the next influenza pandemic is difficult and how scientists can best prepare

Post Your Comments:
(Date:7/1/2015)... ... July 01, 2015 , ... A ... just published a top ten list they hope will guide future mesothelioma research. ... to read it now. , More than 450 mesothelioma patients, caregivers, ...
(Date:7/1/2015)... ... July 01, 2015 , ... Author Francesca Camp wasn’t always a steadfast supporter of ... too did her support of the practice; a terrible car accident years ago left her ... “Do I Need It ? (And What if I Do?): Answers to All Your ...
(Date:7/1/2015)... ... July 01, 2015 , ... After conducting a nationwide ... Tri-City Medical Center in Oceanside, Calif., has hired Cheryle Bernard-Shaw as chief ... compliance adaptation efforts and growing a focus on risk management, Bernard-Shaw will assume ...
(Date:7/1/2015)... ... ... Incentivizing the use of generic drugs has been an easy way for ... 90% off the prices for the brand-name products. But now that generics are experiencing ... of these high-cost generic drugs. The July issue of Atlantic Information Services, Inc.’s (AIS) ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... to the Northbound team as Director of Referral Relations. , Emily originally ... Northbound’s Collegebound, where she designed and implemented unique academic curriculum for clients to ...
Breaking Medicine News(10 mins):Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2
(Date:7/1/2015)... , July 1, 2015 Rock Creek ... company focused on chronic inflammatory disease and neurologic disorders, ... principle study with anatabine citrate, the Company,s lead compound. ... dose of anatabine citrate can significantly inhibit the activation ... The Company is developing this compound in a Phase ...
(Date:7/1/2015)... 2015  BioPharmX Corporation (NYSE MKT: BPMX) today announced ... of 3,636,364 shares of its common stock at a ... has granted the underwriters a 30-day option to purchase ... the public offering price. In addition, Korea ... has agreed to purchase 1,081,081 shares of common stock ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3
Cached News: